QTRTD1 Inhibitors
QTRTD1 Inhibitors are a diverse set of chemical compounds that exert their inhibitory effects by targeting various cellular pathways and processes in which QTRTD1 is involved. For instance, PD 0332991, a CDK4/6 inhibitor, and ZM-447439, an Aurora kinase inhibitor, both impact the cell cycle. Since QTRTD1 is implicated in cell division, these inhibitors lead to a reductionin QTRTD1 activity by halting cell proliferation and disrupting chromosomal dynamics respectively. Rapamycin and LY 294002 exert their effects by inhibiting the mTOR and PI3K/AKT pathways, crucial for cell growth and survival, which would result in a decrease in QTRTD1 function if it is associated with these biological processes. Similarly, PD 98059 and SB 431542 target the MAPK and TGF-beta signaling pathways, pathways potentially linked to QTRTD1's role; thus, their inhibition can result in decreased QTRTD1 activity. Y-27632's inhibition of the Rho/ROCK pathway affects cytoskeletal organization, potentially diminishing QTRTD1 function if it is associated with this structural cellular component.
Furthermore, compounds like Trichostatin A and 2-Deoxy-D-glucose affect histone acetylation and glycolysis respectively, potentially leading to reduced QTRTD1 function through alterations in gene expression and energy metabolism. Brefeldin A disrupts Golgi apparatus function, which could decrease QTRTD1 activity if it relies on protein trafficking or modification within the Golgi. Thapsigargin's disruption of calcium homeostasis could diminish QTRTD1 function if it is regulated by calcium signaling. Lastly, although Omecamtiv mecarbil activates cardiac myosin, its influence on cardiac signaling pathways could indirectly reduce QTRTD1 activity in cardiac muscle contraction if QTRTD1 is involved in such processes. Collectively, these inhibitors demonstrate the multifaceted approaches to diminishing the functional activity of QTRTD1 through interference with specific signaling pathways and cellular processes that are critical for its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
PD 0332991 is a CDK4/6 inhibitor which leads to cell cycle arrest. QTRTD1 is a protein that may play a role in cell division; by halting the cell cycle, PD 0332991 indirectly diminishes the functional activity of QTRTD1 by preventing cellular proliferation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway which is crucial for cell growth and metabolism. By inhibiting this pathway, Rapamycin indirectly leads to a decrease in QTRTD1 activity, assuming QTRTD1 is involved in metabolic regulation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylase (HDAC). By changing the acetylation status of histones, it can alter chromatin structure and gene expression. This may lead to an indirect decrease in QTRTD1 function by altering gene expression profiles. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor. By blocking PI3K, it diminishes the PI3K/AKT signaling pathway which is linked to numerous cellular processes including survival and growth, potentially decreasing QTRTD1 activity if QTRTD1 is part of these cellular processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an inhibitor of MEK which is part of the MAPK pathway. If QTRTD1 is involved in MAPK pathway-regulated processes, inhibiting MEK would lead to a decrease in QTRTD1 activity by impeding the pathway's function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor. The Rho/ROCK pathway is implicated in cytoskeletal organization. Inhibition by Y-27632 could lead to diminished QTRTD1 function by disrupting cellular structures and processes that rely on the proper organization of the cytoskeleton. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB 431542 is an inhibitor of the TGF-beta signaling pathway. If QTRTD1's activity is connected to the TGF-beta pathway, its function would be reduced by the inhibition of this signaling pathway due to SB431542's action. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose acts as a glycolysis inhibitor. If QTRTD1 plays a role in cellular energy metabolism, inhibiting glycolysis would indirectly decrease QTRTD1 activity by limiting energy supply necessary for its function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts Golgi apparatus function. If QTRTD1 is involved in processes related to protein trafficking or modification in the Golgi, then its activity might be diminished due to the disruption caused by Brefeldin A. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that disrupts calcium homeostasis. If QTRTD1 is regulated by or dependent on calcium signaling, inhibition of calcium signaling would lead to diminished QTRTD1 activity. | ||||||